Synapse - Works

Results (988)

Preliminary safety, efficacy, pharmacokinetics, and pharmacodynamics of subcutaneously (SC) administered PF-06863135, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM)

Meeting Abstract

Lesokhin, A. M.; Levy, M. Y.; Dalovisio, A. P.; Bahlis, N. J.; Solh, M.; Sebag, M.; Jakubowiak, A.; Jethava, Y. S.; Costello, C. L.; Chu, M. P.; more...
Blood (2020)

Fulltext@MSK | Save

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study

Meeting Abstract

Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
Blood (2020)

Fulltext@MSK | Save

Evaluation of minimal residual disease (MRD) negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR Study

Meeting Abstract

Landgren, O.; Weisel, K.; Dachs, L. R.; Moreau, P.; Turgut, M.; Hajek, R.; Mollee, P.; Kim, J. S.; Zhang, J.; Go, N.; more...
Blood (2020)

Fulltext@MSK | Save

Assessment of minimal residual disease in a phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma

Meeting Abstract

Landgren, O.; Alsina, M.; Biran, N.; Vesole, D. H.; Wallace, P. K.; Fang, B.; Arnold, G.; Kimball, A.; Siegel, D. S.
Blood (2020)

Fulltext@MSK | Save

Association of patient activity bioprofiles with Hrqol and clinical responses: A prospective novel trial using mobile wearables in newly diagnosed multiple myeloma patients

Meeting Abstract

Korde, N.; Tavitian, E.; Derkach, A.; Zarski, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Lendvai, N.; Smith, E. L.; more...
Blood (2020)

Fulltext@MSK | Save

Treatment of high risk (HR) smoldering multiple myeloma (SMM) with carfilzomib, lenalidomide, and dexamethasone (KRd) followed by lenalidomide maintenance (-R): A phase 2 clinical and correlative study

Meeting Abstract

Kazandjian, D.; Hill, E.; Morrison, C.; Dew, A.; Korde, N.; Mailankody, S.; Manasanch, E. E.; Kwok, M. L.; Bhutani, M.; Tageja, N.; more...
Blood (2020)

Fulltext@MSK | Save

The role of (18)F-FDG-PET/CT in characterizing depth of response in high risk smoldering multiple myeloma patients treated with carfilzomib, lenalidomide, and dexamethasone (KRd)

Meeting Abstract

Hill, E.; Korde, N.; Morrison, C.; Dew, A.; Carpenter, A.; Epstein, M.; Lu, C.; Choyke, P.; Mena, E.; Lindenberg, L.; more...
Blood (2020)

Fulltext@MSK | Save

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone in relapsed or refractory multiple myeloma: Updated efficacy and safety results of the phase 3 CANDOR study

Meeting Abstract

Dimopoulos, M. A.; Quach, H.; Mateos, M. V.; Landgren, O.; Leleu, X.; Siegel, D. S.; Weisel, K.; Gavriatopoulou, M.; Oriol, A.; Rabin, N. K.; more...
Blood (2020)

Fulltext@MSK | Save

Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study

Meeting Abstract

Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
Blood (2020)

Fulltext@MSK | Save

Initial whole genome sequencing of plasma cell neoplasms in first responders and recovery workers exposed to the World Trade Center attack of September 11, 2001

Meeting Abstract

Diamond, B.; Maclachlan, K. H.; Derkach, A.; Yellapantula, V.; Rustad, E. H.; Hultcrantz, M.; Shah, U. A.; Hong, J.; Landau, H. J.; Iacobuzio-Donahue, C.; more...
Blood (2020)

Fulltext@MSK | Save